Gates Scholar Entrepeneurs Fight Tuberculosis

  • May 6, 2008

Gates Scholars Christopher Rumball and Kelly Karns recently returned from Houston, Texas, where they competed in the Rice Business Plan Competition in the hopes of finding investment for their newly-formed company, AutoTB.

A MoneyCNN.com article features the Cambridge team in a roundup of the prestigious competition’s competitors.

Thirty-six of the top MBA/graduate schools from around the world competed in this year’s competition, the largest and richest in the world. Ultimately, more than $675,000 in cash and prizes was awarded. AutoTB was successful in winning the Challenge round in the medical device group, although they did not make the grand final round.

In an endeavour to combine both commercial and social motivations, AutoTB is developing an innovative diagnostic test for tuberculosis, one of the major killers in our world today. The device improves on the current standard of care, resulting in earlier and cheaper diagnoses while maintaining the simplicity and robustness that is necessary for diagnostics in the developing world.

As a result of discussions with potential investors and professional advisors, which is an integral part of the Rice Competition, AutoTB plans to continue advancing its technology and funding-base in the coming months. It will shortly compete in the finals of the Cambridge University Entrepreneurs business plan competition

Latest News

Using Computational Chemistry to make better therapeutics

Aidyn Taishybay [2026] believes firmly that science should make a tangible difference to people.  He wants his work to have direct impact in the world and to make medicines more […]

How do we lead with hope?

Two Gates Cambridge Scholars feature in the final episode of the third series of our podcast So, now what? with a discussion about how to lead with hope. This series […]

The path to democratising algorithmic whispers

Cong Minh Nguyen is an economist who wants to tell stories about how market systems shape people’s lives and how they can be redesigned to expand fairness and opportunity.  He […]

How can we reduce the impact of anti-microbial resistance?

John Wang [2026] believes that the efficiency of a drug treatment is not solely determined by the drug itself, but by how precisely its delivery, targeting and release can be […]